PATTERN_AMBER_1320x780_2 Blogs
Read article Understanding AAV Shedding in Tears: KCAS Bio’s Latest Study

Recently, Matthew Pennington, PhD (one of KCAS’s Senior Scientists) was the senior author on a publication entitled “A Validated Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno Associated Viral Vectors in Bio Shedding Studies of Tears”. Below, Matt explains the significance in what they accomplished…

KCAS-podcast-thumb_TWB-068 Podcasts
Listen to podcast The weekly Bioanalysis Podcast Eps #68: “Molecular Cell & Gene Therapy”

Special guest Carrie Vyhlidal, PhD of KCAS Bio joins John and Dom in the 68th episode of “The Weekly Bioanalysis” to discuss the ways molecular cell & gene therapy services has evolved and why their role will likely become more and more important to the world of bioanalytical…

KCAS-blog-thumb_2023_Biologics Blogs
Read article Addressing Bioanalytical Challenges in Biologics

Biologics are drugs derived from complex molecules like antibodies. Over the last two decades they have re-emerged as…

KCAS-blog-thumb_2023_kcas-flow-for-cgt Blogs
Read article Molecular Bioanalysis for Cell and Gene Therapies

Being that it is a relatively “niche” segment of the industry, there are several key areas that need to be considered in the field of molecular services related to cell and gene therapies. First and foremost, it is important to recognize that regulatory guidelines within this field are…

KCAS-blog-thumb_2022_GLP-CGT Blogs
Read article The Role of GLP Toxicology Studies in Bioanalysis for CGT

Cell and Gene Therapies (CGTs) has an estimated market size value in 2022 of USD 8.22 billion and a revenue forecast in 2030 of USD 24.5 billion. This is a CAGR (compound annual growth rate) of 14.6% from 2022 to 2030. Needless to say, the…

KCAS-blog-thumb_2022_Molecular-CGT Blogs
Read article Cell and Gene Therapy Bioanalytical Solutions

With the extensive advances in technologies like CRISPR and CAR-T, cell and gene therapy has grown to become a viable way for treating Cancer as well as other diseases. Our team has over 100+ years of collective expertise in molecular services using qPCR and ddPCR for support of…

KCAS-blog-thumb_2022_Webinar-CGT-June-2022-1 Webinars
View webinar Upcoming KCAS Webinar (June 24th): “The Age of Cell and Gene Therapies is Upon Us – So What Does That Mean for Bioanalysis?”

Being produced by Xtalks on Friday, June 24, 2022 | 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central) 60 min Webinar Description: Cell and gene therapies (CGTs) are types of treatment that use cellular or genetic material with the goal of treating a disease or a…

car-t-cell-neurotoxicity-management Blogs
Read article Post-Treatment Monitoring in CAR T-Cell Therapy

Introduction of CAR-T Therapy T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR) in CAR-T Cell therapy. The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. (Zhai et al. 2018). Chimeric antigen receptors (CARs) cells have recombinant receptor constructs expressed in T cells to target cells expressing specific antigens.

PATTERN_ORANGE_1320x780_3 Blogs
Read article Clinical Support and Kitting Solutions

The age of cell and gene therapies (CGTs) is upon us! It has been a long road to get to this time. The first gene therapy trial on humans was performed in 1990 by researchers at the National Institutes of Health. The first FDA approved CGT came in 2017. One…

KCAS-blog-thumb_2022_Tissues-Lrg-Mol Blogs
Read article Assessing PD and PK in Non-Liquid Matrices

Tissue and Non-Liquid Matrices (such as cell lines, red blood cells, PBMCs, bone marrow aspirates, and suspension cells) are valuable matrices[] to test for biomarkers (PD) and drug levels (PK). Testing of tissues and…